

105 Rec'd PCT/PTO 10 SEP 1998

FORM PTO-1390 DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93)		ATTORNEY'S DOCKET NO. 120081.403
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/142597
		Unknown
INTERNATIONAL APPLICATION NO. PCT/AU97/00161	INTERNATIONAL FILING DATE 14 March 1997 (14.03.97)	PRIORITY DATE CLAIMED 14 March 1996 (14.03.96)
TITLE OF INVENTION USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE		
APPLICANT(S) FOR DO/EO/US William Butler Cowden, Kevin John Lafferty, Lawrence Scott Gazda		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 to 16 below concern document(s) or information included: <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: Postcard and check for filing fees. 		
Applicant hereby claims priority from Australian Application No. PN 8703 filed 14 March 1996, and from PCT/AU97/00161.		

EXPRESS MAIL MAILING LABEL

NUMBER EM149491268US


DATE OF DEPOSIT 10 September 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington D.C. 20231-6001

Signature

09/142597

300 Rec'd PCT/PTO 11 SEP 1998

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Unknown		INTERNATIONAL APPLICATION NO. PCT/AU97/00161		ATTORNEY'S DOCKET NUMBER 120081.403	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$ 910.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$ 700.00 No international preliminary examination fee paid to USPTO (cu CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$ 770.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1070.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$1,070.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$130.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	32 - 20 =	12	x \$ 22.00	\$264.00	
Independent Claims	4 - 3 =	1	x \$ 82.00	\$82.00	
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$260.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,806.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (NOTE: 37 CFR 1.9, 1.27, 1.28)				\$0.00	
SUBTOTAL =				\$1,806.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$0.00	
TOTAL NATIONAL FEE =				\$1,806.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property)				\$0.00	
TOTAL FEES ENCLOSED =				\$1,806.00	
				Amount to be refunded:	\$.00
				charged	\$.00
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1,806.00</u> cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-1090</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:			 SIGNATURE		
David J. Maki SEED AND BERRY 6300 Columbia Center 701 5th Avenue Seattle, WA 98104-7092 United States of America (206) 622-4900			David W. Parker NAME		
			37.414 REGISTRATION NUMBER		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: William Butler Cowden, Kevin John Lafferty,
Lawrence Scott Gazda
Attorney's Docket No: 120081.403
Application No.: 09/142,597
Filed: September 10, 1998
For: USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE
DISEASE

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 C.F.R. §§ 1.9(f) AND 1.27(d) -- NONPROFIT ORGANIZATION)

I declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization: The Australian National University
Address of Organization: Acton, Australian Capital Territory
2601, Australia

TYPE OF ORGANIZATION:

- ☒ university or other institution of higher education
☐ tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3))
☐ nonprofit scientific or educational under statute of a state of the United States of America
(Name of state: _____)
(Citation of statute: _____)
☐ would qualify as tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3)) if located in the United States of America
☐ would qualify as nonprofit scientific or educational under statute of a state of the United States of America if located in the United States of America
(Name of state: _____)
(Citation of statute: _____)

I declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. § 1.9(e) for purposes of paying reduced fees under 35 U.S.C. §§ 41(a) and 41(b) with regard to the invention entitled:

USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE

by inventors William Butler Cowden, Kevin John Lafferty, Lawrence Scott Gazda, as described in:

- ☐ the specification filed herewith.
☒ Application No. 09/142,597, filed September 10, 1998
☐ Patent No. _____, issued _____

I declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above-identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 C.F.R. § 1.9(c) or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).*

*NOTE: Separate verified statements are required from each named person, concern and organization having rights to the invention averring to his/its status as a small entity. (37 C.F.R. § 1.27)

FULL NAME BIODISCOVERY LTD
 ADDRESS Level 10, 384 Victoria Street, Darlinghurst, New South Wales 2010 Australia

- ☐ individual
☒ small business concern
☐ nonprofit organization

FULL NAME _____
 ADDRESS _____

- ☐ individual
☐ small business concern
☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earlier of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that the making of willfully false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Professor John RICHARDS
TITLE IN ORGANIZATION Deputy Vice Chancellor
ADDRESS OF PERSON SIGNING Chancellery, The Australian National University,
Acton, 2601, Australian Capital Territory, 2601, Australia
SIGNATURE *John Richards* DATE 14 / 2 / 1999.

U:\float\sharons\0401

William Butler Cowden
Kevin John Lafferty
Lawrence Scott Gazda

Applicant or Patentee: _____ Attorney's
Serial or Patent No.: 09/142597 Docket No.: 120081.403
Filed or Issued: 10 September 1998
For: "Use of coxiella bacteria to treat autoimmune disease"

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN BIODISCOVERY LTD.
ADDRESS OF CONCERN Level 10, 384 Victoria Street, Darlinghurst,
New South Wales, 2010, Australia

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled "Use of coxiella bacteria to treat autoimmune disease" by inventor(s) William Butler Cowden, Kevin John Lafferty & Lawrence Scott Gazda described in

- ☐ the specification filed herewith
☒ application serial no. 09/142597, filed 10 September 1998
☐ patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Y JOAN DAWES
TITLE OF PERSON OTHER THAN OWNER Y CHIEF EXECUTIVE OFFICER
ADDRESS OF PERSON SIGNING Level 10, 384 Victoria Street, Darlinghurst,
New South Wales, 2010, Australia
SIGNATURE Y Joan Dawes DATE 17 FEB 1999.

2 PAGES

09 / 14 25 97

WO 97/33614

PCT/AU97/00161

28 Rec'd PCT/PTO 10 SEP1998

USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE

The present invention relates generally to a method for ameliorating the adverse effects of
5 autoimmune conditions and to therapeutic conditions useful for same. More particularly, the
present invention provides a method for the prophylaxis and/or treatment of insulin-dependent
diabetes mellitus (IDDM) by preventing, inhibiting, delaying onset of, or otherwise
ameliorating the effects of the disease. The present invention further provides a method for
the prophylaxis and/or treatment of pancreatic beta cell destruction in islet tissue transplanted
10 into recipients. The present invention also provides therapeutic compositions useful in the
prophylaxis and/or treatment of IDDM and pancreatic beta cell destruction.

Throughout this specification and the claims which follow, unless the context requires
otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be
15 understood to imply the inclusion of a stated integer or group of integers but not the exclusion
of any other integer or group of integers.

Bibliographic details of the publications referred to by author in this specification are collected
at the end of the description.

20

IDDM is a debilitating, chronic cell mediated autoimmune disease characterised by
lymphocytic infiltration of the pancreatic islets and lymphocyte mediated destruction of
insulin-producing beta-cells (Bach 1994, Honeyman and Harrison, 1993) and is defined by
the presence of hyperglycemia. Type 1 diabetes, or IDDM, occurs where an individual's own
25 immune system destroys the cells responsible for insulin production; the beta cells residing
in the islets of Langerhans of the pancreas. IDDM in humans, in the non-obese diabetic
mouse (NOD mouse [Makino *et al*, 1980; Kanazawa *et al*, 1984]) and in the BB rat is an
autoimmune disease associated with the development of auto-antibodies reactive to islet-
associated antigens (Atkinson *et al*, 1986). Susceptibility to the development of disease both
30 in humans and in non-human animals is under genetic control. Genes of the major

- 2 -

histocompatibility complex (MHC), specifically those found in the class II MHC region, which control structures involved in the presentation of antigen to the cellular components of the immune system are to a large extent responsible for the disease-prone status (Davis *et al.*, 1989).

5

In animal models, a single immunostimulation with live, infectious BCG (*Mycobacterium bovis*; Bacille Calmette-Guérin) vaccination (Yagi *et al.*, 1991) or powerful immuno-adjuvants based on heat-killed *Mycobacterium tuberculosis* (or *Mycobacterium butyricum*) either early or late in the disease process, can largely suppress the development or progression of disease
10 respectively (reviewed in Bach, 1994). Freund's Complete Adjuvant (FCA) [often referred to as complete Freund's adjuvant or CFA], which consists of a suspension of heat-killed *M. tuberculosis* (or *M. butyricum*) in mineral oil together with a surfactant is considered to be a particularly powerful immunological adjuvant. Immunostimulation with a single injection of FCA has been shown to substantially protect both NOD mice (Sadelain *et al.*, 1990a;
15 McInerney *et al.*, 1991) and BB rats (Sadelain *et al.*, 1990b) from developing diabetes.

Immuno-adjuvants such as bacterial lipopolysaccharide (LPS) or muramyl dipeptide (MDP) which are not based upon either live or heat-killed *Mycobacterium sp.* are not effective in preventing diabetes.

20

Another biological response modifier, OK-432, prepared from streptococci, when administered to NOD mice, has been shown to prevent the onset of diabetes until mice reach 24 weeks of age (Toyota *et al.*, 1986); no information exists showing whether or not these animals remain free of diabetes once the therapy is discontinued. It has also been shown that
25 the immunomodulating drug quinoline-3-carboxamide (Linomide) when given continuously in the drinking water to NOD mice, starting at a young age (5 weeks), will block the onset of diabetes until the mice are at least 40 weeks old (Gross *et al.*, 1994). However, this agent is not as effective when therapy is started on mice which are 16 weeks old; in this case the cumulative incidence of diabetes is 28% by the time the mice are 42 weeks old even though

30

- 3 -

the drug is given on a continuous basis (Gross *et al.*, 1994).

FCA appears to induce cell-mediated protection against development of diabetes. It has, for example, been shown that spleen cells taken from NOD mice, which had been treated with
5 FCA, were capable of suppressing the response of co-cultured control syngeneic spleen cells to mitogens (Sadelain *et al.*, 1990a; McInerney *et al.*, 1991). When spleen cells are taken from BCG vaccinated NOD mice and passaged into naive NOD mice, the latter are protected from developing diabetes (Harada *et al.*, 1990; Yagi *et al.*, 1991). The same effect has been observed in FCA-treated BB rats (Qin *et al.*, 1992). It should be noted that others have found
10 FCA to be less effective than BCG in transferring protection in this manner (Qin *et al.*, 1993; Ulaeto *et al.*, 1992).

Recurrence of disease in grafted tissue is a major factor which interferes with the transplantation of pancreatic islets into spontaneously diabetic NOD mice. Currently it is not
15 possible to successfully transplant islets into animals that have developed disease spontaneously without recourse to extensive immunosuppression (Wang *et al.*, 1991). Recurrence of disease can, however, be blocked in spontaneously diabetic NOD mice if they are treated with FCA (Wang *et al.*, 1992; Lakey *et al.*, 1992) or BCG (Lakey *et al.*, 1994) prior to transplantation.

20

Immunostimulation of NOD mice by either BCG or FCA does not totally block the autoimmune response, instead the response is converted from a destructive into a non-destructive form of auto-immunity (Shehadeh *et al.*, 1993). Thus, functionally these agents do not prevent or reverse autoimmunity directed against islet tissue, although they do prevent
25 development of insulin-dependent diabetes.

It would appear, therefore, that deviation of the immune response away from destructive autoimmunity by immunostimulation could offer a benign approach to the prevention of diabetes and the development of more effective means for the transplantation of islets in the
30 case of existing disease.

- 4 -

However, neither FCA nor BCG is an ideal therapeutic agent for preventing the development of IDDM. Despite the fact that FCA is a very powerful immuno-adjuvant, it has not found wide-spread use outside the laboratory because of the adverse tissue reaction (severe ulceration) it provokes in mammals. In most countries, FCA is banned from veterinary use and, of course, it cannot be used in humans. BCG is an infectious agent which cannot be given to certain individuals, especially those who are immunosuppressed.

In work leading to the present invention, the inventors sought to develop agents capable of blocking the development of IDDM in humans which are sufficiently benign for general use and most effective in terms of deviating the immune response away from destructive autoimmunity.

Accordingly, one aspect of the present invention contemplates a method for preventing, inhibiting, delaying onset of or otherwise ameliorating the effects of an autoimmune disease in a mammal, said method comprising administering to said mammal an autoimmune-preventing effective amount of a species of *Coxiella* or one or more antigenic components therefrom or analogous or homologous components thereof.

Another aspect of the present invention provides a method for prolonging survival of islet tissue transplanted into a mammal, said method comprising administering into said mammal an effective amount of a species of *Coxiella* or one or more antigenic components therefrom or analogous or homologous components thereof.

Still a further aspect of the present invention is directed to a therapeutic composition for use in preventing, inhibiting, delaying onset of or otherwise ameliorating the effects of an autoimmune disease in a mammal said composition comprising a species of *Coxiella* or one or more antigenic components therefrom or analogous or homologous components thereof and one or more pharmaceutically acceptable carriers and/or diluents.

Yet still another aspect of the present invention relates to the use of a species of *Coxiella* or

- 5 -

one or more antigenic components therefrom or analogous or homologous components thereof in the manufacture of a medicament for the treatment of an autoimmune disease in a mammal.

Coxiella is a genus of Gram negative bacteria of the Rickettsiaceae. The only known species to date is *Coxiella burnetii* which is the causative agent of Q fever in man. Reference herein to "*Coxiella*" species, therefore includes *C. burnetii* or an organism related thereto at the functional level. The present invention requires that the *Coxiella* species be attenuated, killed or otherwise rendered non-infectious prior to use.

- 10 The use of non-infectious agents in the prophylaxis and/or treatment of autoimmune disease conditions offers a major advantage in clinical terms. Infectious agents, even those such as BCG, frequently pose a problem if administered to an immunocompromised individual and, while FCA might be effective in humans, its use is precluded by the severe ulcerative skin lesions which develop following its use. In accordance with the present invention, an ideal agent would be capable of blocking the induction of the autoimmune disease as well as inhibiting disease recurrence in transplanted islet tissue in diabetic patients.

The present invention is particularly directed and exemplified with reference to IDDM as the autoimmune disease. This is done, however, with the understanding that the present invention extends to a range of autoimmune conditions and in particular, autoimmune conditions which can be treated by deviating an immune response away from destructive autoimmunity. Examples of autoimmune conditions contemplated herein other than IDDM include but are not limited to pernicious anaemia, autoimmune chronic hepatitis, ulcerative colitis, primary biliary cirrhosis multiple sclerosis and systemic lupus erythematosus (SLE).

25

According to a preferred embodiment, the present invention contemplates a method of preventing, inhibiting, delaying onset of or otherwise ameliorating the effects of IDDM in a mammal, said method comprising administering to said mammal an autoimmune-preventing effective amount of a species of *Coxiella* or one or more antigenic components therefrom or analogous or homologous components thereof.

30

- 6 -

The present invention extends to the prophylaxis or treatment of any mammal such as but not limited to a human, primate, livestock animal (eg. sheep, cow, horse, pig, donkey), companion animal (eg. dog, cat), laboratory test animal (eg. mouse, rat, guinea pig, rabbit, hamster) or captive wild animal (eg. fox, deer, kangaroo).

5

Accordingly, a preferred aspect of the present invention is directed to a method of preventing, inhibiting, delaying onset of or otherwise ameliorating the effects of IDDM in a human, said method comprising administering to said mammal an autoimmune-preventing effective amount of a species of *Coxiella* or one or more antigenic components therefrom or analogous
10 or homologous components thereof.

The present invention particularly relates to *C. burnetii* or a related organism or an antigenic component thereof or an analogous or homologous component thereof. A particularly useful form of *C. burnetii* is a killed preparation of the bacterium such as a heat killed or formulin
15 killed preparation. One such useful form is QVAX which is a Q fever vaccine or Q fever complement fixing antigen phase I (QFA) [both available from CSL Limited, Melbourne, Australia]. The present invention extends however to live, attenuated strains of *C. burnetii* or to preparations of the bacterium killed or rendered non-infectious by other means.

20 The present invention further contemplates antigenic components of *C. burnetii* such as a lysed preparation of the whole organism, a membrane/wall preparation, an endospore preparation or one or more purified or partially purified antigenic molecules therefrom or analogous or homologous components thereof.

25 Accordingly, a particularly preferred embodiment of the present invention is directed to a method for preventing, inhibiting, delaying onset of or otherwise ameliorating the effects of IDDM or pancreatic beta cell destruction in islet tissue transplantation recipients in a human, said method comprising administering to said human, an effective amount of killed or attenuated *C. burnetii* or an antigenic component thereof or analogous or homologous
30 components thereof.

- 7 -

Preferably, QVAX or QFA is administered.

Generally, administration is for a time and under conditions sufficient for the immune response to deviate from a destructive immune response to a non-destructive immune
5 response.

This and other aspects of the present invention are predicted in part of the surprising result that a Q fever antigen (*C. burnetii*), and in particular killed *C. burnetii* in the form of, for example, QFA or QVAX when injected into NOD mice inhibits diabetes in a high percentage
10 ($\geq 90\%$) of treated mice. The agents of the present invention are not recognised immuno-
adjuvants and yet are as effective as either BCG or FCA in preventing the development of diabetes in NOD mice.

The present invention contemplates *Coxiella* sp and in particular *C. burnetii* and antigenic
15 components thereof as well as recombinant or synthetic forms of the antigenic components
and analogues or homologues thereof from another source. The latter molecules may be identified, for example, by natural product screening of coral, ocean beds, plants, soil and other microorganisms. These molecules may structurally mimic the antigenic components from *C. burnetii* or may only functionally mimic these components by preventing, inhibiting,
20 delaying onset of, curing or otherwise ameliorating the effects of an autoimmune disease and in particular IDDM. One convenient way of screening for analogues or homologues is *via* anti-idiotypic antibody screening. For example, antibodies are raised to particular antigenic components of *C. burnetii* and anti-idiotypic antibodies raised to the first mentioned antibodies. The anti-idiotypic antibodies are then used to screen for molecules capable of
25 binding or otherwise interacting with these antibodies.

Alternatively, chemical analogues may be made from isolated antigenic components of *C. burnetii* or from analogous or homologous components thereof.

30 Analogues of *C. burnetii* antigenic components contemplated herein include, but are not limited

- 8 -

to, where the antigenic component is proteinaceous, modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues. Such analogues are particularly
5 useful if they are more stable when used for administration in a vaccine formulation.

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic
10 anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

15 The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

20

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-
25 chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides.

30 Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form

- 9 -

a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

5

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-
10 isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 1.

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having $(CH_2)_n$ spacer groups with $n=1$ to
15 $n=6$, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α -methylamino acids, introduction of double bonds between C_α and C_β atoms of amino
20 acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

The present invention further contemplates chemical analogues of *C. burnetii* antigenic
25 components capable of acting as antagonists or agonists of same or which can act as functional analogues of the antigenic components. Chemical analogues may not necessarily be derived from *C. burnetii* molecule but may share certain conformational similarities. Alternatively, chemical analogues may be specifically designed to mimic certain physiochemical properties of the antigenic components. Chemical analogues may be chemically synthesised or may be
30 detected following, for example, natural product screening.

5

TABLE 1

Non-conventional 5 amino acid	Code	Non-conventional amino acid	Code
α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
10 carboxylate		L-N-methylaspartic acid	Nmasp
aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
aminonorbornyl-	Norb	L-N-methylglutamine	Nmgln
carboxylate		L-N-methylglutamic acid	Nmglu
cyclohexylalanine		Chexa L-N-methylhistidine	Nmhis
15 cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
D-alanine	Dal	L-N-methylleucine	Nmleu
D-arginine	Darg	L-N-methyllysine	Nmlys
D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
20 D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
D-isoleucine	Dile	L-N-methylproline	Nmpro
D-leucine	Dleu	L-N-methylserine	Nmser
25 D-lysine	Dlys	L-N-methylthreonine	Nmthr
D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
D-phenylalanine	Dphe	L-N-methylvaline	Nmval
D-proline	Dpro	L-N-methylethylglycine	Nmetg
30 D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug

- 12 -

	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgab
5	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
10	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
15	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
20	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
25	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
30	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr

- 13 -

	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
5	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
10	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
15	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
20	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
25	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr

- 14 -

L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe
N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine		carbamylmethyl)glycine	
1-carboxy-1-(2,2-diphenyl-	Nmbc		
5 ethylamino)cyclopropane			

In a preferred embodiment of the present invention, the human targeted for therapy would be known to be likely to develop IDDM or is a patient who has recently been diagnosed to
 10 be in the early stages of IDDM or is a patient suffering from IDDM and who could be transplanted with islet tissue from a non-diabetic donor. The human may also be an "at risk" individual due to certain environmental conditions or may have a genetic propensity to develop IDDM such as due to a family history of the disease.

15 Another aspect of the present invention contemplates a method for prolonging survival of islet tissue transplanted into a human, said method comprising administering into said mammal an effective amount of a species of *C. burnetii* or one or more antigenic components therefrom or analogous or homologous components thereof.

20 Yet another aspect of the present invention provides a therapeutic composition for use in preventing, inhibiting, delaying onset of or otherwise ameliorating the effects of an autoimmune disease in a mammal said composition comprising a species of *Coxiella* or one or more antigenic components therefrom or analogous or homologous components thereof and one or more pharmaceutically acceptable carriers and/or diluents.

25

Preferably, the mammal is a human. Preferably the autoimmune condition is IDDM or pancreatic beta cell destruction in islet tissue of transplantation recipients. Preferably the *Coxiella* species is *C. burnetii* or an antigenic component or an analogous or homologous component thereof or is a killed or otherwise non-infectious in attenuated form of the
 30 bacterium. Most preferably, the administered agent is QFA or QVAX or functionally

- 15 -

equivalent forms thereof.

The term "active component" is hereinafter used to refer to a *Coxiella* species and in particular *C. burnetii* or to antigenic components therefrom or analogous or homologous
5 components thereof.

The active component is administered in therapeutically effective amounts. A therapeutically effective amount means that amount necessary at least partly to attain the desired effect, or to inhibit or delay the onset of, inhibit the progression of, or halt or prevent altogether, the
10 onset or progression of the particular condition being treated such as IDDM. Such amounts will depend, of course, on the particular condition being treated, the severity of the condition and individual patient parameters including age, physical condition, size, weight and concurrent treatment. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is preferred generally
15 that a maximum dose be used, that is, the highest safe dose according to sound medical judgement. It will be understood by those of ordinary skill in the art, however, that a lower dose or tolerable dose may be administered for medical reasons, psychological reasons or for virtually any other reasons.

20 The formulation of such therapeutic compositions is well known to persons skilled in this field. Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in
25 the art, and it is described, by way of example, in *Remington's Pharmaceutical Sciences*, 18th Edition, Mack Publishing Company, Pennsylvania, USA. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the pharmaceutical compositions of the present invention is contemplated.

30 Therapeutic formulations suitable for injectable use include sterile aqueous solutions (where

- 16 -

water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The present invention also contemplates administration *via* topically applied compositions where active components may be modified to permit entry *via* the skin. It must be stable under the conditions of manufacture and storage and must be
5 preserved against the contaminating action of microorganisms such as bacteria and fungi.

The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for
10 example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
15 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active components in the required amount in the appropriate solvent with various of the other ingredients enumerated above.
20 Generally, dispersions are prepared by incorporating the various active components, sterilized where appropriate, into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any
25 additional desired ingredient.

Preferred compositions or preparations according to the present invention contains between about 0.1 μ g and about 2000 mg of active component. Other ranges contemplated herein include from about 1 μ g to about 1000 mg, from about 10 μ g to about 100 mg and from about
30 100 μ g to about 50 mg. Where killed or attenuated or otherwise non-infectious organisms

- 17 -

are administered, a suitable range is from about 10^2 to about 10^6 cells/ml of therapeutic composition being administered to a patient. The present invention also contemplates amounts outside this range, the important feature being an amount which is effective to induce a deviation from destructive autoimmunity to a non-destructive form of autoimmunity.

5

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the
10 active component, use thereof in the therapeutic compositions is contemplated. Supplementary active components can also be incorporated into the compositions. Examples of supplementary components include various cytokines, insulin, antibacterial agents and immune potentiating molecules.

15 It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The
20 specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.

25

The principal active component is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage form can, for example, contain the principal active component in amounts ranging from about 0.1 μg to about 2000 mg. Expressed in
30 proportions, the active component is generally present in from about 0.5 μg to about 2000

- 18 -

mg/ml of carrier. Expressed in cellular terms, the unit dosage may range from 10^2 to 10^{16} cells/ml of carrier or diluent. In the case of compositions containing supplementary active component, the dosages are determined by reference to the usual dose and manner of administration of the said components. The present invention also contemplates dosage ranges
5 outside these amounts.

The active components of the present invention may be administered alone or in combination with other therapeutic molecules such as molecules which reduce effects of the autoimmune pathology associated with IDDM. A single dose may be administered and is preferred
10 although multiple doses may be required with intervals of from minutes to hours, days to weeks or months to years.

Reference herein to "preventing" IDDM includes total prevention of IDDM or substantial prevention for a limited time or even substantially indefinitely or delaying onset of IDDM or
15 reducing the severity or otherwise ameliorating the effects of IDDM. For example, in humans, prevention includes but is not limited to delaying onset for from 1 to 60 years or from 2 to 30 years or from 3 to 15 years. As a test system for prevention in mice may range from weeks to years.

20 It has been shown that the active components of the present invention including one or more Q fever antigens and in particular killed *C. burnetii* are more efficacious than either FCA or BCG in protecting beta cells from autoimmune destruction in NOD mice. Thus, NOD mice treated with doses of either FCA, BCG or Q fever antigen(s), did not develop IDDM. Significantly, more viable beta cells were found in the pancreases of mice which had been
25 treated with the active components than in the mice treated with either FCA or BCG.

NOD female mice between 120 and 180 days of age, which had become diabetic spontaneously, treated with an active component of the present invention and then transplanted with syngeneic islet tissue essentially as described in Bowen *et al*, (1980),
30 maintained normal blood glucose levels. Control mice, treated with saline instead of an

- 19 -

active component and then similarly transplanted with syngeneic islet tissue, become diabetic, for example within about 10 days of tissue transplantation. Histological sections of transplanted tissue taken from the saline treated group, at the time they become diabetic, show a massive inflammatory infiltrate into the transplanted tissue, with essentially complete
 5 beta cell destruction. Histological sections taken for example one month after treatment from the animals treated with an active component show little or no inflammatory infiltrate and the beta cells are intact.

The present invention is further described by reference to the following non-limiting Figures
 10 and Examples. It is to be understood, however, that the Examples are included solely for the purposes of exemplifying the present invention, and should not be understood in any way as a restriction on the broader aspects of the subject invention as set out above.

In the Figures:

15

Figure 1 is a graphical representation showing the prevention of IDDM in NOD mice following administration of QFA:

- Saline (12/16 diabetic)
- 20 ◇ Saline (8/13 diabetic)
- FCA (2/17 diabetic)
- QFA 200 μ l (1/14 diabetic)

Figure 2 is a graphical representation showing the prevention of IDDM in NOD mice
 25 following administration of QFA:

- Saline (8/13 diabetic)
- QFA 70 μ l (2/15 diabetic)
- QFA 200 μ l (1/14 diabetic)

30

- 20 -

In the following examples, all specific pathogen-free NOD mice were obtained from the Animal Breeding Establishment, The Australian National University, Canberra, ACT, Australia. Mice were housed under specific pathogen-free conditions with sterilised micro-isolator cages and bedding. Sterilised food and water were provided *ad libitum*. Cages were
5 changed in laminar flow hoods using sterile technique by a laboratory assistant who was dedicated solely to this task and who was not responsible for the maintenance of any other animals. Cages were housed in hepa filtered ventilation racks with a 12 hour day night cycle. Routine serological monitoring was performed by the Murine Virus Monitoring Service, (Primary Industries, Adelaide, South Australia), for evidence of infection by any
10 of 15 different murine viruses. Since the implementation of this procedure, the NOD mouse colony used in this study has tested negative for all of these viruses.

EXAMPLE 1

15 This example demonstrates the effectiveness of a single 200 μ l dose of Q fever complement fixing antigen Phase I (QFA) in inhibiting the occurrence of IDDM in NOD mice.

Female NOD littermates between 64 and 69 days of age were divided into two groups and injected intraperitoneally (ip) with either 200 μ l of Q fever complement fixing antigen phase
20 I (obtained from CSL, Melbourne Australia) or 200 μ l of saline solution. Fifteen mice were injected with QFA while 14 littermates received saline solution. One animal from each group was found dead of unknown causes during the course of the experiment.

For comparison, in a similar manner, 17 female NOD littermates between the ages of 64 and
25 85 days of age were injected in the right rear footpad with 50 μ l complete Freund's adjuvant (FCA) (Bacto lot # 784560) given as an emulsion in an equal volume of normal saline; 16 littermates received saline solution only.

Mice in all of the four groups were checked three times per week for elevated glucose
30 concentrations in their urine (Tes-Tape, Eli Lilly and Co, Indianapolis, IN, USA). When

- 21 -

mice were found to have raised urinary glucose levels, whole blood glucose levels were determined with a Companion 2 Sensor (Medisense, Cambridge, MA, USA). Where two consecutive daily blood glucose readings above the 95 % confidence interval for NOD mice in this colony (3.9-9.1 mmol/L) were obtained, the animal was deemed to be diabetic. 5 Animals were monitored until they reached 300 days of age or became diabetic. The results of this experiment are shown in Figure 1.

As indicated in Figure 1, at 300 days of age, 2 out of 17 mice (12 %) in the FCA treated group had become diabetic while 12 out of 16 mice (75 %) of their saline treated littermates 10 became diabetic. At 300 days of age only 1 out of 14 (7 %) of the QFA treated mice had developed diabetes compared to 8 out of 13 (62 %) of their saline treated littermates.

EXAMPLE 2

15

This example demonstrates the effectiveness of single 20 or 70 μ l doses of QFA in inhibiting the occurrence of IDDM in NOD mice.

Female NOD mice between 62 and 72 days of age were injected intraperitoneally (ip) with 20 either 70 μ l of QFA or 20 μ l of QFA. Fifteen mice were injected with 70 μ l of QFA and 15 mice received 20 μ l QFA. One animal from the 20 μ l group was found dead of unknown causes during the course of the experiment. The 200 μ l saline injected group of female NOD mice from Example 1 served as control animals. Mice were checked three times a week for elevated glucose levels in their urine (Tes-Tape, Eli Lilly and Co, Indianapolis, IN, 25 USA). When positive for urinary glucose, whole blood glucose levels were determined with a Companion 2 sensor (Medisense, Cambridge, MA, USA). Where two consecutive daily blood glucose readings above the 95 % confidence interval for NOD mice in this colony (3.9-9.1 mmol/L) were obtained, the animal was deemed to be diabetic. The animals were monitored until they reached 260 days of age or became diabetic. The results of this 30 experiment are shown in Figure 2. At 260 days of age only 2 out of 15 (13 %) of the group

- 22 -

treated with 70 μ l of QFA and 1 out of 14 (7%) of the 20 μ l QFA treated group had become diabetic, compared to 8 out of 13 (62%) of the saline treated NOD mice from Example 1 that served as controls for this experiment.

5

EXAMPLE 3

This example demonstrates that QFA is more efficacious than either FCA or BCG in protecting beta cells from autoimmune destruction in NOD mice.

- 10 A group of 10 specific pathogen-free, 61- 66 day old female NOD mice were injected in both rear footpads with 40 μ l (total dose 80 μ l) reconstituted freeze-dried live BCG (Pasteur Merieux, Lyon, France). A second group of 17, 64-85 day old female NOD animals, were injected with FCA emulsified with an equal volume of normal saline (50 μ l in right hind footpad). A third group of 14 age-matched female NOD mice were injected, ip, with 200
- 15 μ l of QFA. Two additional groups of 14 age-matched female NOD mice received either 70 or 20 μ l of QFA, ip. When the mice had reached 300 days of age, 10, 13 and 11 mice from the BCG, FCA and each of the QFA treated groups respectively (all nondiabetic) were sacrificed by cervical dislocation and their pancreases removed for histological sectioning and examination. Thirteen age-matched nondiabetic female NODs were also sacrificed and
- 20 their pancreases similarly examined. Pancreases were fixed in 10% v/v neutral buffered formalin for 18 hours. Immunohistochemistry was used to stain for the presence of insulin and glucagon positive islets (DAKO Corporation, Carpinteria, CA). Serial 5 μ m sections were stained for either insulin or glucagon and examined by light microscopy. As shown in Table 1 only 16% of islets in the BCG treated group stained positive for insulin production,
- 25 52% of islets in the FCA treated group stained positive for insulin and in the QFA treated group 87%, 77% and 75% of islets stained positive for insulin production in the 200, 70 and 20 μ l treatment groups respectively. Seventy-three percent of the islets examined from pancreases of age-matched female non-diabetic NOD mice had insulin positive islets while 27% of the islets were positive for glucagon only.

30

- 23 -

TABLE 1

Treatment	% Insulin positive islets*	% Collapsed Islets * (Glucagon only)
BCG	16 (11/69)	84 (58/69)
FCA	52 (31/60)	48 (29/60)
5 QFA (200 μ l)	87 (105/121)	13 (16/121)
QFA (70 μ l)	77 (40/52)	23 (12/52)
QFA (20 μ l)	75 (41/55)	25 (14/55)
Age matched females	73 (22/30)	27 (8/30)

- 10 *Figures in parentheses represent the number of positive or collapsed islets/total number examined.

EXAMPLE 4

- 15 This example demonstrates the effectiveness of Q fever antigen treatment in preventing the recurrence of IDDM in spontaneously diabetic NOD mice transplanted with syngeneic islet tissue.

Donor animals, four to eight week old NOD female mice, were anaesthetised with an
 20 intraperitoneal injection of avertin solution. A curved 27 gauge needle was inserted into the common bile duct at the hilus after the distal end of the duct had been clamped. Approximately 3 ml of cold collagenase P (Boehringer Mannheim, Castle Hill, NSW, Australia) made to 2.5 mg/ml in Hanks balanced salt solution + 0.05% w/v BSA was injected immediately after dissection of the intrathoracic aorta. The pancreas was then
 25 excised and digested while held stationary in a 37°C water bath for 15 minutes and islets were hand-picked and transplanted essentially as described in Bowen *et al.*

Recipient mice, female NODs which had been diabetic for less than 2 weeks but for at least 3 days prior to transplantation and which had a mean blood glucose levels of 29.7 ± 1.38

- 24 -

mmol/L (range 21.2 - 33.4 mmol/L) on the day of engraftment, following anaesthesia (avertin, i.p.), received 450 islets under the left kidney capsule in a clot of recipient blood. These animals were divided into two groups. The treatment group, n=9, received QFA, 70 μ l, s.c., at the time of transplantation and the control group, n=10 received an injection of saline, 70 μ l, s.c. at the time of transplantation.

Blood glucose levels were determined for all islet-engrafted mice beginning on the day following transplantation. In the majority of cases in both the treated and control groups, a few days were required for normoglycaemia to be established. All 10 untreated islet-transplanted mice were hyperglycaemic (blood glucose > 22 mmol/L) by day 10 post-transplantation. Mice which were treated with QFA were largely protected against disease recurrence as evidenced by their blood glucose levels (mean blood glucose levels 8.17 ± 0.67) on day 10 post-transplantation. Thus, in the QFA-treated islet-transplanted group 6 out of 9 mice were protected from disease recurrence for greater than 30 days. One mouse out of 9 became diabetic on day 25 post-transplantation and two mice failed to become normoglycaemic following engraftment.

EXAMPLE 5

This example demonstrates that *C. burnetii* vaccine (QVAX) is effective in inhibiting the occurrence of IDDM in NOD mice.

Female NOD littermates 72 days of age were divided into two groups and injected subcutaneously with either 100 μ l of QVAX (obtained from CSL, Melbourne, Australia) or 100 μ l of saline solution. Ten mice were treated with QVAX while 10 littermates received saline solution.

Mice in both groups were checked three times per week for elevated glucose concentrations in their urine (Tes-Tape, Eli Lilly and Co., Indianapolis, IN). When mice were found to have raised urinary glucose levels, whole blood glucose levels were determined with a

- 25 -

Companion 2 Sensor (Medisense, Cambridge, MA, USA). Where two consecutive daily blood glucose readings above the 95 % confidence interval for NOD mice in this colony (3.9-9.1 mmol/L) were obtained, the animal was deemed to be diabetic. Animals were monitored until they reached 100 days of age or became diabetic.

5

None of the QVAX treated mice became diabetic during this period while 2 out of 10 of the saline treated mice became diabetic by 100 days of age. At 200 days of age, 9 out of 10 QVAX-treated mice were protected from developing diabetes while 9 out of 10 saline-treated mice developed diabetes.

10

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this
15 specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

Atkinson, M. A., et al *Diabetes*, **35**, 894-898, 1986.

Bach, J. F.. *Endocr. Rev.*, **15**, 516-54, 1994.

Bowen, K. M., et al *Diabetes*, **29**, 98-104, 1980.

Davis, C. B., et al *J. Exp. Med.*, **169**, 2239-2244, 1989.

Gross, D. J., et al *Diabetologia*, **37**, 1195-1201, 1994.

Harada, M., et al *Diabetes Res. Clin. Pract.*, **8**, 85-89, 1990.

Honeyman, M.C. and Harrison, L.C. *Springer Semn. Immunopathol.*, **14**, 253, 1993.

Kanazawa, Y. et al *Diabetologia.*, **27**, 113-115, 1984.

Lakey, J. R., et al *Transplant. Proc.*, **24**, 2848, 1992.

Lakey, J. R., et al *Transplantation*, **57**, 1213-1217, 1994.

Makino S. et al *Exp. Anim.*, **29**, 1-13. 1980.

McInerney, M. F., et al *Diabetes*, **40**, 715-725, 1991.

Qin, H.-Y., *Autoimmunity*, **12**, 193-199, 1992.

- 27 -

Qin, H.-Y., *et al J. Immunol.* **150**, 2072-2080, 1993.

Sadelain, M. W. J., *et al Diabetes*, **39**, 583-589, 1990a.

Sadelain, M. W. J., *et al Journal of Autoimmunity*, **3**, 671-680, 1990b.

Shehadeh, N. N., *et al J. Autoimmun.*, **6**, 291-300, 1993.

Toyota, T., *et al Diabetes*, **35**, 496-499, 1986.

Ulaeto, D., *et al Proc. Natl. Acad. Sci. (USA)*. **89**, 3927-3931, 1992.

Wang, T., *et al Diabetes*, **41**, 114-117, 1992.

Yagi, H., *et al Cell. Immunol.*, **138**, 142-149, 1991.

CLAIMS:

1. A method for preventing, inhibiting, delaying onset of or otherwise ameliorating the effects of an autoimmune disease in a mammal, said method comprising administering to said mammal an autoimmune-preventing effective amount of a species of *Coxiella* or one or more antigenic components therefrom or analogous or homologous components thereof.
2. A method according to claim 1 wherein the mammal is a human or laboratory test animal.
3. A method according to claim 2 wherein the autoimmune condition is insulin-dependent diabetes mellitus (IDDM).
4. A method according to claim 1, wherein the autoimmune disease adversely effects the survival of pancreatic islet tissue transplanted into a mammal.
5. A method according to claim 3 or 4 wherein the species of *Coxiella* is *Coxiella burnetii*.
6. A method according to claim 3 or 4 wherein the *C. burnetii* is in the form of a killed preparation.
7. A method according to claim 3 or 4 wherein the antigenic component from *C. burnetii* is a Q fever antigen.
8. A method according to claim 7 wherein the Q fever antigen is Q fever complement fixing antigen phase I (QFA).
9. A method for prolonging survival of islet tissue transplanted into a mammal, said method comprising administering into said mammal an effective amount of a species of

Coxiella or one or more antigenic components therefrom or analogous or homologous components thereof.


10. A method according to claim 9 wherein the mammal is a human or laboratory test animal.
11. A method according to claim 10 wherein the species of *Coxiella* is *C. burnetii*.
12. A method according to claim 11 wherein the *C. burnetii* is in the form of a killed preparation.
13. A method according to claim 11 wherein the antigenic component from *C. burnetii* is a Q fever antigen.
14. A method according to claim 13 wherein the Q fever antigen is QFA.
15. A therapeutic composition for use in preventing, inhibiting, delaying onset of or otherwise ameliorating the effects of an autoimmune disease in a mammal said composition comprising a species of *Coxiella* or one or more antigenic components therefrom or analogous components thereof and one or more pharmaceutically acceptable carriers and/or diluents.
16. A therapeutic composition according to claim 15 wherein the mammal is a human or laboratory test animal.
17. A therapeutic composition according to claim 16 wherein the autoimmune disease is IDDM.
18. A therapeutic composition according to claim 17 wherein the species of *Coxiella* is *C. burnetii*.

- 30 -

19. A therapeutic composition according to claim 18 wherein the *C. burnetii* is in the form of a killed preparation.
20. A therapeutic composition according to claim 15 wherein the antigenic component is a Q fever antigen.
21. A therapeutic composition according to claim 20 wherein the Q fever antigen is QFA.
22. Use of a species of *Coxiella* or one or more antigenic component components therefrom or analogous or homologous components thereof in the manufacture of a medicament in the treatment of an autoimmune disease in a mammal.
23. Use according to claim 22 wherein the mammal is human or laboratory test animal.
24. Use according to claim 23 wherein the autoimmune disease is IDDM.
25. Use according to claim 23 wherein the species of *Coxiella* is *C. burnetii*.
26. Use according to claim 23 wherein the *C. burnetii* is in the form of a killed preparation.
27. Use according to claim 26 wherein the antigenic component is a Q fever antigen.
28. Use according to claim 26 wherein the Q fever antigen is QFA.


1/2

FIGURE 1



2/2

FIGURE 2



DECLARATION AND POWER OF ATTORNEY

As the below-named inventors, we declare that:

Our residences, post office addresses, and citizenships are as stated below under our names.

We believe we are the original, first, and joint inventors of the invention entitled "USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE," which is described and claimed in the specification and claims of Patent Application No. 09/142,597, which we filed in the United States Patent and Trademark Office on September 10, 1998, and for which a patent is sought.

We have reviewed and understand the contents of the foregoing specification, including the claims, as amended by any amendment specifically referred to herein (if any).

We acknowledge our duty to disclose information of which we are aware which is material to the patentability and examination of this application in accordance with 37 C.F.R. § 1.56(a).


We hereby claim foreign priority benefits under 35 U.S.C. § 119 of the foreign patent application listed below:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:			
COUNTRY	APPLICATION NUMBER	DATE OF FILING	PRIORITY CLAIMED UNDER 35 USC 119
PCT	PCT/AU97/00161	March 14, 1997	Yes
Australia	PN 8703	March 14, 1996	Yes

40 We hereby appoint RICHARD W. SEED, Reg. No. 16,557; ROBERT J. BAYNHAM, Reg. No. 22,846; EDWARD W. BULCHIS, Reg. No. 26,847; GEORGE C. RONDEAU, JR., Reg. No. 28,893; DAVID H. DEITS, Reg. No. 28,066; WILLIAM O. FERRON, JR., Reg. No. 30,633; PAUL T. MEIKLEJOHN, Reg. No. 26,569; DAVID J. MAKI, Reg. No. 31,392; RICHARD G. SHARKEY, Reg. No. 32,629; DAVID V. CARLSON, Reg. No. 31,153; MAURICE J. PIRIO, Reg. No. 33,273; KARL R. HERMANN, Reg. No. 33,507; DAVID D. MCMASTERS, Reg. No. 33,963; MICHAEL J. DONOHUE, Reg. No. 35,859; CHRISTOPHER J. DALEY-WATSON, Reg. No. 34,807; STEVEN D. LAWRENZ, Reg. No. 37,376; ROBERT G. WOOLSTON, Reg. No. 37,263; ELLEN M. BIERMAN, Reg. No. 38,079; PAUL T. PARKER, Reg. No. 38,264; JOHN C. STEWART, Reg. No. 40,188; ANN T. KADLECEK, Reg. No. 39,244; DAVID W. PARKER, Reg. No. 37,414; BRIAN G. BODINE, Reg. No. 40,520; FRANK ABRAMONTE, Reg. No. 38,066; E. RUSSELL TARLETON, Reg. No. 31,800;

FREDERICK M. FLIEGEL, Reg. No. 36,138; JAN CAROL LITTLE, Reg. No. 41,181; THOMAS L. EWING, Reg. No. 34,328; KEVIN S. COSTANZA, Reg. No. 37,801; DALE C. BARR, Reg. No. 40,498; KEVIN S. ROSS, Reg. No. 42,116; PAUL F. RUSYN, Reg. No. 42,118; JOHN M. WECHKIN, Reg. No. 42,216; THOMAS E. LOOP, Reg. No. 42,810; STEPHEN J. ROSENMAN, Reg. No. 43,058; BRIAN L. JOHNSON, Reg. No. 40,033; JAMES D. WHITE, Reg. No. P-43,985; KIMTON N. ENG, Reg. No. P-43,605; SUSAN DENISE BETCHER, Reg. No. P-43,498; and DENNIS M. DEGUZMAN, Reg. No. 41,702, comprising the firm of SEED AND BERRY LLP, 6300 Columbia Center, Seattle, Washington 98104-7092, as our attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Please direct all telephone calls to **David J. Maki** at (206) 622-4900 and telecopies to (206) 682-6031.

We further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that the making of willfully false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and may jeopardize the validity of any patent issuing from this patent application.


William Butler Cowden

Date 4 February 1999

Residence : City of Kambah
Country of Australia AUX
Citizenship : Australia
P.O. Address : 56 Urambi Village
Kambah, Australian Capital Territory
2902, Australia

Kevin John Lafferty

Date

Residence

:

City of Curtin

Country of Australia AUX

Citizenship

:

Australia

P.O. Address

:

63 McColloch Street

Curtin, Australian Capital Territory

2905, Australia

Lawrence Scott Gazda

Date

Residence

:

City of Hawker

Country of Australia AUX

Citizenship

:

United States of America

P.O. Address

:

19/30 Springvale Drive

Hawker, Australian Capital Territory

2614, Australia